Wholesalers Say Novo Can't Duck GLP-1 Antitrust Suits
Drug buyers want a New York federal judge to preserve proposed class claims accusing Novo Nordisk of paying Teva to delay generic competition with its Victoza GLP-1 drug, arguing that whatever...To view the full article, register now.
Already a subscriber? Click here to view full article